The Implications of Recent Datasets for the Current and Future Management of Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia — An ASCO/EHA 2026 Review — Webinar Proceedings

Faculty

TARGET AUDIENCE
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia.

LEARNING OBJECTIVES

• Develop an understanding of published clinical research findings with CD19-targeted monoclonal antibodies for newly diagnosed and relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).
• Appraise the biological rationale for, available research findings with and current clinical role of antibody-drug conjugates for R/R DLBCL.
• Evaluate the mechanism of action of and available clinical trial findings with bispecific T-cell engaging antibodies alone and in combination with other agents for FL, DLBCL and other forms of lymphoma.
• Appreciate the biological rationale for, available data with and current clinical role of covalent and noncovalent Bruton tyrosine kinase (BTK) and Bcl-2 inhibitors for mantle cell lymphoma.
• Recognize the prognostic and clinical significance of various biomarkers in chronic lymphocytic leukemia (CLL), such as del(17p), TP53 mutations and IGHV gene rearrangements, and use this information to individualize the selection of systemic therapy for patients with newly diagnosed disease.
• Review the similarities and differences between covalent and noncovalent BTK inhibitors, and assess the implications for the efficacy and tolerability of these agents.
• Evaluate available Phase III data demonstrating the efficacy of BTK inhibitors as first-line therapy for CLL.
• Appreciate the scientific rationale for the investigation of covalent and noncovalent BTK inhibitors in combination with Bcl-2 inhibition, and review recently presented data with this strategy for newly diagnosed and R/R CLL.
• Recall new data with agents and strategies currently under investigation for CLL and various non-Hodgkin lymphoma subtypes, and discuss ongoing trial opportunities with eligible patients.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 1.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
To receive credit for this activity, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Kahl — Consulting Agreements: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeOne, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Lilly, Octapharma, Roche Laboratories Inc; Data and Safety Monitoring Boards/Committees: Acrotech Biopharma, Bristol Myers Squibb, Foresight Diagnostics, a wholly-owned subsidiary of Natera Inc, Nurix Therapeutics Inc, PeproMene Bio Inc. Dr Sharman — Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Genentech, a member of the Roche Group, Lilly, Merck, Roche Laboratories Inc; Data and Safety Monitoring Boards/Committees: BeOne. Dr Siddiqi — Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Genentech, a member of the Roche Group, Gilead Sciences Inc, Merck, Pfizer Inc; Contracted Research: Bristol Myers Squibb.

MODERATOR — Dr Love  is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, and Verastem Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Genmab US Inc and Lilly.

Release date: September 2026
Expiration date: September 2027

Dr Sharman

Ahn I et al. A phase 2 study of fixed-duration pirtobrutinib and obinutuzumab in previously untreated CLL. EHA 2026;Abstract S148.

Cheah CY et al. First-line treatment of CLL/SLL with the all-oral combination of sonrotoclax and zanubrutinib achieves undetectable minimal residual disease rates of >90%, including in patients with del(17p)/TP53. EHA 2026;Abstract S145.

Davids MS et al. Fixed duration pirtobrutinib plus venetoclax–rituximab versus venetoclax–rituximab for patients with previously treated CLL/SLL: A phase 3, randomized trial (BRUIN CLL-322). EHA 2026;Abstract LB5001.

Fischer K et al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Final results of the randomized CLL14 study. EHA 2026;Abstract S146.

Kater AP et al. Fixed duration venetoclax plus epcoritamab shows favorable tolerability and high response rates with early molecular responses in R/R CLL/SLL: Interim analysis of the randomized HOVON 165/AETHER trial. EHA 2026;Abstract S153.

Munir T et al. Updated efficacy and safety data from an ongoing phase 1a/b trial of the BTK degrader bexobrutideg (NX-5948) in patients with CLL across lines of therapy. EHA 2026;Abstract S150.

Seymour JF et al. Safety of fixed-duration (FD) acalabrutinib-venetoclax combinations in patients (pts) with chronic lymphocytic leukemia (CLL) stratified by age: Post hoc analysis of the phase 3 AMPLIFY trial. EHA 2026;Abstract PF614.

Stilgenbauer S et al. BGB-16673, a Bruton tyrosine kinase (BTK) degrader, in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): A phase 1 CADANCE-101 study update. EHA 2026;Abstract S152.

Wierda W et al. Pirtobrutinib in treatment-naïve patients with CLL/SLL: Pooled results from BRUIN CLL-313 and BRUIN CLL-314. ASCO 2026;Abstract 7044.

Dr Siddiqi

Budde LE et al. Mosunetuzumab plus polatuzumab vedotin versus rituximab, gemcitabine and oxaliplatin in large B-cell lymphoma: Updated efficacy and safety from the phase 3 SUNMO study including in patient subgroups. EHA 2026;Abstract PF968.

Chihara D et al. Phase 2 trial of epcoritamab in combination with rituximab-mini CVP for older unfit/frail or anthracycline-ineligible adult patients with newly diagnosed diffuse large B-cell lymphoma: Interim futility analysis. ASCO 2026;Abstract 7002.

Flinn I et al. Fixed-duration subcutaneous (SC) mosunetuzumab (Mosun) in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Interim analysis and patient-reported outcomes (PROs) from the phase 2 MorningSun study. ASCO 2026;Abstract 7029.

Fox CP et al. Results from EPCORE DLBCL-1: Randomized phase 3 study of epcoritamab (epcor) vs investigator’s choice chemoimmunotherapy (CIT) in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). EHA 2026;Abstract S235.

Genmab A/S. Genmab announces positive phase 3 results for epcoritamab plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma, demonstrating statistically significant improvement in progression-free survival [press release]. June 29, 2026.

Glass B et al. Polatuzumab vedotin plus rituximab, ifosfamide, carboplatin, etoposide (Pola-R-ICE) vs R-ICE as second line treatment in large B cell lymphoma (LBCL). Final analysis of a randomized phase 3 study. EHA 2026;Abstract S237.

Harkins RA et al. Outcomes by LymphoMAP archetypes in untreated diffuse large B-cell lymphoma from the POLARIX trial. ASCO 2026;Abstract 7017.

Hoffmann MS et al. Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD, + Pola-RCHP in patients (pts) with newly diagnosed aggressive B-cell lymphoma (a-BCL): Safety and 12-month (mo) efficacy results. ASCO 2026;Abstract 7011.

Jerkeman M et al. Safety data and initial pooled efficacy data from the Nordic Lymphoma Group phase 3 POLAR BEAR trial in elderly or frail patients with diffuse large cell lymphoma – R-Pola-mini-CHP vs R-mini-CHOP. EHA 2026;Abstract S238.

Lenz G et al. Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): A global, phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2026;407(10547):2528-41. Abstract

Matasar M et al. Multivariable analyses (MVAs) of overall survival (OS) in the phase 3 SUNMO, STARGLO, and POLARGO trials in relapsed/refractory large B-cell lymphoma (LBCL). ASCO 2026;Abstract 7093.

Thieblemont C et al. Sustained remissions beyond 4 years with epcoritamab monotherapy: Long-term follow-up results from the pivotal EPCORE NHL-1 trial in patients with relapsed or refractory large B-cell lymphoma. EHA 2026;Abstract PF977.

Dr Kahl

A phase 3 randomized double-blind multicenter study of sonrotoclax plus zanubrutinib versus placebo plus zanubrutinib in patients with relapsed/refractory mantle cell lymphoma. NCT06742996

A randomized phase 3 trial of continuous vs intermittent maintenance therapy with zanubrutinib as upfront treatment in older patients with mantle cell lymphoma. NCT05976763

BeOne Medicines Ltd. BeOne Medicines announces positive phase 3 results for Brukinsa in frontline mantle cell lymphoma [press release]. June 30, 2026.

Budde LE et al. CELESTIMO single arm extension: Safety and efficacy of mosunetuzumab plus lenalidomide in patients with R/R follicular lymphoma. EHA 2026;Abstract PS2043.

Budde LE et al. Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: A phase 2 study. Blood 2026;148(6):682-92. Abstract

Cheah CY et al. Surovatamig (AZD0486) plus rituximab in previously untreated follicular lymphoma (FL): Initial safety data from the phase 3 SOUNDTRACK-F1 trial. EHA 2026;Abstract S228.

Eyre TA et al. Phase I/II study of sonrotoclax (BGB-11417) monotherapy in patients with mantle cell lymphoma previously treated with anti-CD20 therapy and a Bruton tyrosine kinase inhibitor. J Clin Oncol 2026;44(23):2233-43. Abstract

Karimi Y et al. Fixed-duration glofitamab monotherapy in relapsed/refractory (R/R) mantle cell lymphoma (MCL) with/without prior Bruton’s tyrosine kinase inhibitor (BTKi) exposure: Updated data after a 3.5-year follow-up. ASCO 2026;Abstract 7006.

Morillo D et al. Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD ± rituximab (R) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL): Phase (Ph) 1/2 study long-term follow-up (f/u). EHA 2026;Abstract S227.

Scholz CW et al. Phase 3 inMIND study of tafasitamab (tafa) plus lenalidomide (len) and rituximab (R) for relapsed or refractory follicular lymphoma (R/R FL): Outcomes in patients with or without high-risk factors. EHA 2026;Abstract PS2048.

Tessoulin B et al. Clinically relevant subgroup analysis from the randomized phase 3 EPCORE FL-1 trial: Treatment (tx) effect of epcoritamab with lenalidomide and rituximab (R2) in R/R follicular lymphoma (FL). EHA 2026;Abstract S229.

Wang ML et al. Pirtobrutinib in covalent Bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma. J Clin Oncol 2023;41(24):3988-97. Abstract